Santhera und ReveraGen starten schrittweise NDA-Einreichung bei der FDA für Vamorolone zur Behandlung von Duchenne-Muskeldystrophie
March 29, 2022 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 29. März 2022 - Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. (US: privat) geben den Beginn der schrittweisen Einreichung eines Zulassungsantrags (NDA, new drug...
Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
March 29, 2022 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, March 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce the initiation of a rolling new drug application (NDA) submission to...
Santhera und ReveraGen präsentieren Daten zur Wirksamkeit und Verträglichkeit von Vamorolone an der 2022 MDA Konferenz
March 15, 2022 02:05 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, und Rockville, MD, USA, 15. März , 2022 - Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. geben bekannt, dass sie an der 2022 Muscular Dystrophy Association (MDA)...
Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
March 15, 2022 02:05 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with...
Santhera vollzieht ordentliche Kapitalerhöhung zur Schaffung eigener Aktien für künftige Finanzierungen
March 15, 2022 02:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 15. März...
Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
March 15, 2022 02:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland,...
Santhera gibt vorläufige Finanzergebnisse für 2021 bekannt und erhöht das Aktienkapital zur Schaffung eigener Aktien für künftige Finanzierungen
March 11, 2022 01:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc-Mitteilung gemäss Art. 53 KR Start der Einreichung des...
Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
March 11, 2022 01:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Initiation of rolling...
Santhera unterzeichnet Gentherapie-Vereinbarung mit SEAL Therapeutics
February 28, 2022 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 28. Februar 2022 - Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer Vereinbarung mit SEAL Therapeutics für einen Gentherapieansatz zur Behandlung von kongenitaler...
Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
February 28, 2022 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, February 28, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular...